دوره 9، شماره 2 - ( 9-1401 )                   جلد 9 شماره 2 صفحات 23-18 | برگشت به فهرست نسخه ها


XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

ghazavi A, khaki M, Mosayebi G, Keshavarzian N, Navabi P, Ganji A. Efficacy of Two Vaccine Platforms against SARS-CoV-2. vacres 2022; 9 (2) :18-23
URL: http://vacres.pasteur.ac.ir/article-1-312-fa.html
Efficacy of Two Vaccine Platforms against SARS-CoV-2. Vaccine Research. 1401; 9 (2) :18-23

URL: http://vacres.pasteur.ac.ir/article-1-312-fa.html


چکیده:   (1526 مشاهده)
Introduction: Several vaccine platforms have been designed to elicit an effective immune response against SARS-CoV-2. This study was aimed to evaluate the humoral immune response in Iranian people vaccinated with both inactivated virus vaccines and vector vaccine platforms. Methods: The study enrolled 360 vaccinated individuals with inactivated virus vaccines (BBIBP-CorV and Covaxin) and vector vaccine platforms (AstraZeneca and Sputnik V). Serum samples were collected for each volunteer on days 14 to 21 after vaccination, and anti–SARS-CoV-2 spike receptor-binding domain (RBD) IgG concentrations were analyzed by ELISA. Results: Higher antibody titers were observed in participants vaccinated with vector vaccines compared with those immunized with inactivated virus, especially in subjects who received two doses of AstraZeneca. (AstraZeneca: 204.19 U/mL [95% CI, 175.5-232.2] vs. Sputnik V :114.67 U/mL [95% CI, 99.54-129.8]; P = 0.007). It was also observed that antibody titers were not significantly different between the two groups receiving inactivated vaccines (P = 0.86). Our results indicated that 28% of the population vaccinated with Covaxin and 32% of people vaccinated with BBIBP-CorV showed no response to the vaccine. There was also a statistically insignificant difference between age, BMI, and gender with antibody level in each group of vaccines (P > 0.05). Conclusion: Based on a limited population data , our study showed that the viral vector-based vaccines produced higher levels of neutralized antibodies than the inactivated vaccines, and their rate of non-response was lesser.
متن کامل [PDF 546 kb]   (634 دریافت)    
نوع مطالعه: پژوهشي | موضوع مقاله: Immune responses tovaccines
دریافت: 1401/9/29

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
CAPTCHA

بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به Vaccine Research می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2024 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.